central nervous system therapeutics Archives

Could Praxis Precision Medicines’ Phase 3 ulixacaltamide data redefine the treatment pathway in essential tremor?

By Soujanya Ravi on April 13, 2026 Pharma & Biotech

Praxis Precision Medicines’ positive Phase 3 ulixacaltamide data could reshape essential tremor treatment. Discover what this means for neurology and investors.

Why Newron’s EUR 38m financing matters for Phase III evenamide development in treatment-resistant schizophrenia

By Pallavi Madhiraju on February 17, 2026 Pharma & Biotech

Newron Pharmaceuticals secures up to EUR 38 million to advance evenamide Phase III trials. Find out what this means for treatment-resistant schizophrenia.

Clearmind Medicine Inc. and Polyrizon Ltd. target formulation risk in MEAI’s addiction program

By Soujanya Ravi on February 6, 2026 Pharma & Biotech

Discover how Clearmind Medicine Inc.’s intranasal MEAI strategy could reshape CNS drug delivery and clinical outcomes. Read the analysis.